Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 4/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | PER2 | O15055 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL662370 | 0.84 | PTGER4 (0.32) | PTGER4MCHR1CNR2CYP11B2S1PR1 | |
| SCHEMBL4410334 | 0.83 | CYP11B2 (0.38) | PTGER4MCHR1CYP11B2S1PR1CYP11B1 | |
| SCHEMBL1666145 | 0.82 | S1PR1 (0.38) | PTGER4MCHR1CACNA2D1CNR2CYP11B2 | |
| SCHEMBL661430 | 0.81 | CNR2 (0.40) | MCHR1CACNA2D1CNR2S1PR1 | |
| SCHEMBL4408630 | 0.81 | CYP11B2 (0.52) | PTGER4CYP11B2CYP11B1JAK2JAK1 | |
| SCHEMBL661470 | 0.81 | RORC (0.39) | CNR2S1PR1JAK2JAK1TYK2 | |
| SCHEMBL663298 | 0.80 | TLR7 (0.39) | CNR2 | |
| SCHEMBL27673238 | 0.80 | CNR2 (0.42) | MCHR1CACNA2D1CNR2CYP11B2S1PR1 | |
| SCHEMBL4408059 | 0.78 | P2RX3 (0.40) | CNR2JAK2JAK1TYK2JAK3 | |
| SCHEMBL27930243 | 0.77 | PTGER4 (0.48) | PTGER4CYP11B2S1PR1CYP11B1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763644-B2 | Imidazole derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2010-07-27 | — | — | US | claimed |
| EP-2050736-A1 | Imidazole derivatives, processes for preparing them and their uses | UCB Pharma, S.A. (BE) | 2009-04-22 | — | — | EP | claimed |
| US-20080081832-A1 | Imidazole derivatives, processes for preparing them and their uses | UCB, S.A. | 2008-04-03 | — | — | US | claimed |
| JP-2007513105-A | — | — | 2007-05-24 | — | — | JP | claimed |
| EP-1706376-A1 | IMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2006-10-04 | — | — | EP | claimed |
| US-20050137241-A1 | Imidazole derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2005-06-23 | — | — | US | claimed |
| WO-2005054188-A1 | IMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2005-06-16 | — | — | WO | claimed |
| US-20240293363-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | UNIV JOHNS HOPKINS (US) | 2024-09-05 | — | — | US | disclosed |
| US-20230277501-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| US-20230033195-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2023-02-02 | — | — | US | disclosed |
| US-20220265685-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2022-08-25 | — | — | US | disclosed |
| US-20220218665-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | UNIV JOHNS HOPKINS (US) | 2022-07-14 | — | — | US | disclosed |
| US-11160785-B2 | Methods and compositions for improving cognitive function | AGENEBIO INC. (US) | 2021-11-02 | — | — | US | disclosed |
| WO-2010044878-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-04-22 | — | — | WO | disclosed |
| EP-2050736-A1 | Imidazole derivatives, processes for preparing them and their uses | UCB Pharma, S.A. (BE) | 2009-04-22 | — | — | EP | disclosed |
| US-20080081832-A1 | Imidazole derivatives, processes for preparing them and their uses | UCB, S.A. | 2008-04-03 | — | — | US | disclosed |
| US-7244747-B2 | Imidazole derivatives, processes for preparing them and their uses | UCB, S.A. (BE) | 2007-07-17 | — | — | US | disclosed |
| EP-1706376-A1 | IMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2006-10-04 | — | — | EP | disclosed |
| US-20050137241-A1 | Imidazole derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2005-06-23 | — | — | US | disclosed |
| WO-2005054188-A1 | IMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11160785-B2 | Methods and compositions for improving cognitive function | BACE2, BACE1, GRIN2A | PTGER4 4434/4885MCHR1 1229/4885CACNA2D1 1326/4885 |
| US-20240293363-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE2, RAB2A, VAMP8 | PTGER4 3911/4885MCHR1 1595/4885CACNA2D1 183/4885 |
| US-20220218665-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE2, RAB2A, VAMP8 | PTGER4 3911/4885MCHR1 1595/4885CACNA2D1 183/4885 |
| US-20230277501-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GRIN2A, CHRNA2, SYNGR2 | PTGER4 4619/4885MCHR1 2664/4885CACNA2D1 155/4885 |
| US-20220265685-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | BACE1, BACE2, ACHE | PTGER4 3990/4885MCHR1 3581/4885CACNA2D1 539/4885 |
| US-20080081832-A1 | Imidazole derivatives, processes for preparing them and their uses | CYP3A4, PPIP5K2, CYP2C19 | PTGER4 1029/4885MCHR1 4504/4885CACNA2D1 2857/4885 |
| US-20230033195-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GRIN2D, GRIN2A, SLC18A2 | PTGER4 4213/4885MCHR1 2670/4885CACNA2D1 152/4885 |
| US-20050137241-A1 | Imidazole derivatives, processes for preparing them and their uses | CYP3A4, PPIP5K2, CYP2C19 | PTGER4 1029/4885MCHR1 4504/4885CACNA2D1 2857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.